457 results on '"Yerushalmi R"'
Search Results
2. Pregnancy After Breast Cancer in Young BRCA Carriers: An International Hospital-Based Cohort Study
3. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
4. Pregnancy After Breast Cancer in Young BRCA Carriers
5. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial
6. Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation
7. 192MO DESTINY-Breast04 subgroup analyses of trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with human epidermal growth factor 2 (HER2)-low, estrogen-receptor (ER) expression immunohistochemistry (IHC) 0-10% metastatic breast cancer (mBC)
8. 186O Patient-reported outcomes (PROs) from DESTINY-Breast02, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2–positive (HER2+) metastatic breast cancer (mBC)
9. P169 Clinical outcomes in patients (pts) with estrogen receptor (ER)+ stage I breast cancer (BC) and Recurrence Score (RS) 26–30: Real-world data
10. Evaluation of European-based polygenic risk score for breast cancer in Ashkenazi Jewish women in Israel
11. 149P Clinical outcomes in ER+ breast cancer patients with recurrence score 26-30-guided therapy: Real-world data
12. 152P Molecular characterization by the 21-gene breast cancer (BC) Recurrence Score (RS) test of BRCA1/2 mutation carriers (mBRCA1/2) versus the general BC patient (pt) population
13. 1815O Breastfeeding after breast cancer in young BRCA carriers: Results from an international cohort study
14. Breast cancer risk after age 60 among BRCA1 and BRCA2 mutation carriers
15. Brentuximab vedotin in combination with or without donor lymphocyte infusion for patients with Hodgkin lymphoma after allogeneic stem cell transplantation
16. Oncotype-DX recurrence score distribution in breast cancer patients with BRCA1/2 mutations
17. Fludarabine and treosulfan compared with other reduced-intensity conditioning regimens for allogeneic stem cell transplantation in patients with lymphoid malignancies
18. Atomic and Molecular Layer Deposition of Chiral Thin Films Showing up to 99% Spin Selective Transport
19. P1108: HIGH COMPLETE RESPONSE RATE FOLLOWING POINT-OF-CARE ANTI CD19 CAR T-CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA
20. Overall survival in the OlympiA phase Ill trial of adjuvant olaparib in patients with germime pathogenic variants in BRCA1/2 and high-risk, early breast cancer
21. Is breast-conserving therapy a safe option for patients with tumor multicentricity and multifocality?
22. VP1-2022: Pre-specified event driven analysis of Overall Survival (OS) in the OlympiA phase III trial of adjuvant olaparib (OL) in germline BRCA1/2 mutation (gBRCAm) associated breast cancer
23. Breast cancer risk after age 60 among BRCA1 and BRCA2 mutation carriers
24. Breast carcinoma—rare types: review of the literature
25. Decline in pulmonary function in patients with breast cancer receiving dose-dense chemotherapy: a prospective study
26. Do alternative methods of measuring tumor size, including consideration of multicentric/multifocal disease, enhance prognostic information beyond TNM staging in women with early stage breast cancer: an analysis of the NCIC CTG MA.5 and MA.12 clinical trials
27. Breast cancer and leptomeningeal disease (LMD): hormone receptor status influences time to development of LMD and survival from LMD diagnosis
28. Secondary malignancies after allogeneic stem-cell transplantation in the era of reduced-intensity conditioning; the incidence is not reduced
29. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
30. Allo-SCT for AML and MDS with treosulfan compared with BU-based regimens: reduced toxicity vs reduced intensity
31. 388P Subgroup analysis of patients (pts) with HER2-low metastatic breast cancer (mBC) with brain metastases (BMs) at baseline from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC)
32. 369P The impact of germline BRCA mutations in locally advanced, triple-negative breast cancer (TNBC) treated with platinum- based neoadjuvant chemotherapy
33. SURVIVAL ADVANTAGE FOR PATIENTS WITH AML/MDS GIVEN ALLOGENEIC SCT USING MYELOABLATIVE VERSUS REDUCED INTENSITY CONDITIONING (RIC) MAY BECOME APPARENT 5-10 YEARS AFTER TRANSPLANTATION: RIC STUDIES MAY NEED TO BE REVISITED AFTER LONG-TERM FOLLOW-UP: PH-O073
34. MISSING HLA C GROUP 1 LIGAND IN PATIENTS WITH AML AND MDS IS ASSOCIATED WITH REDUCED RISK OF RELAPSE AND IMPROVED SURVIVAL AFTER ALLOGENEIC STEM CELL TRANSPLANTATION WITH FLUDARABINE AND TREOSULFAN REDUCED TOXICITY CONDITIONING: PH-O046
35. Ibritumomab tiuxetan (Zevalin) combined with reduced-intensity conditioning and allogeneic stem-cell transplantation (SCT) in patients with chemorefractory non-Hodgkin's lymphoma
36. Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine/busulfan
37. National comprehensive cancer network recommendations for drugs without US food and drug administration approval in metastatic breast cancer: A cross-sectional study
38. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity
39. Tumor markers in metastatic breast cancer subtypes: frequency of elevation and correlation with outcome
40. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: long-term follow-up
41. Fludarabine and treosulfan conditioning for allogeneic stem cell transplantation; a dose- intense regimen with limited toxicity: P961
42. Cyclosporine and methotrexate compared with cyclosporine and mycophenolate as GvHD prevention regimens in allogeneic stem cell transplantation from unrelated donors; relative outcomes are dependent on disease status at transplantation: P447
43. Reduced toxicity myeloablative conditioning regimens compared with standard myeloablative conditioning prior to allogeneic stem cell transplantation in AML and MDS; more favourable toxicity profile but more limited leukaemia control in advanced disease: O289
44. Pretransplantation administration of anti-thymocyte globulin as part of the conditioning induces T regulatory cells - Clinical implications: O426
45. Treatment of donor graft failure with autologous or allogeneic stem cell boost or a second allogeneic transplantation based on chimerism testing
46. Fludarabine and treosulfan; a novel reduced-toxicity regimen with effective anti-leukaemia activity in patients with AML and MDS
47. The concordance of treatment decision guided by oncotype and the PREDICT tool in early stage breast cancer
48. Evolution in the risk of adverse events of adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer
49. BASELINE CLINICAL AND PET-CT TUMOR BURDEN PARAMETERS DO NOT PREDICT OUTCOME OF RELAPSE/REFRACTORY AGGRESSIVE B CELL LYMPHOMA PATIENTS TREATED WITH ANTI-CD19 CAR T-CELLS
50. PS1030 COMPLETE REMISSION WITH INCOMPLETE BLOOD COUNT RECOVERY IS A STRONG PREDICTOR OF NON-RELAPSE MORTALITY IN ACUTE MYELOID LEUKEMIA PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.